Literature DB >> 8990063

A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism.

A Negrotti1, S Calzetti.   

Abstract

The natural course of calcium-entry blocker-induced parkinsonism was evaluated in 13 elderly patients previously exposed to cinnarizine or flunarizine or both for a median period of 7 months. Clinical assessments were carried out before drug discontinuation and twice thereafter over a period lasting < or = 7 years. None of the patients showed a full recovery of extrapyramidal signs, indicating that the long-term prognosis of the parkinsonism is less benign than previously reported. Two main patterns of clinical outcome were recognized (i.e., "remittent" and "persistent and not progressive" parkinsonism), whereas the development of a progressive disorder was observed only in one patient. No significant correlation was found between the patterns of outcome and some clinical variables, such as total duration of exposure to cinnarizine and flunarizine, cumulative drug dosages, and age at onset of parkinsonism. There was no significant difference in terms of family history of essential tremor or parkinsonism or both among patients with the two main patterns of clinical course.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8990063     DOI: 10.1002/mds.870120119

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  13 in total

Review 1.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.

Authors:  Hsiu-Li Lin; Hsiu-Chen Lin; Yuan-Fu Tseng; Shih-Chang Chen; Chien-Yeh Hsu
Journal:  Eur J Clin Pharmacol       Date:  2016-12-16       Impact factor: 2.953

3.  Ameliorative effect of flunarizine in cisplatin-induced acute renal failure via mitochondrial permeability transition pore inactivation in rats.

Authors:  Arunachalam Muthuraman; Shailja Sood; Sumeet Kumar Singla; Ajay Rana; Atinderjeet Singh; Amandeep Singh; Jai Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-31       Impact factor: 3.000

4.  Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.

Authors:  Renato P Munhoz; Delcio Bertucci Filho; Hélio A G Teive
Journal:  Neurol Sci       Date:  2016-11-16       Impact factor: 3.307

5.  Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.

Authors:  H Matsuo; A Matsui; R Nasu; H Takanaga; N Inoue; F Hattori; H Ohtani; Y Sawada
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

6.  Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine.

Authors:  Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2013-10-30       Impact factor: 3.575

7.  Modulation of visceral nociception, inflammation and gastric mucosal injury by cinnarizine.

Authors:  Omar M E Abdel-Salam
Journal:  Drug Target Insights       Date:  2007-02-12

8.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

9.  Cardiovascular Autonomic Dysfunction in Patients with Drug-Induced Parkinsonism.

Authors:  Joong Seok Kim; Dong Woo Ryu; Ju Hee Oh; Yang Hyun Lee; Sung Jin Park; Kipyung Jeon; Jong Yun Lee; Seong Hee Ho; Jungmin So; Jin Hee Im; Kwang Soo Lee
Journal:  J Clin Neurol       Date:  2016-10-07       Impact factor: 3.077

10.  Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study.

Authors:  Foad Taghdiri; Mansoureh Togha; Soodeh Razeghi Jahromi; Farshid Refaeian
Journal:  Springerplus       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.